Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms.

Continuous (Kliogest) and sequential (Trisequens) oestrogen-progestogen treatment were compared in a randomized, parallel, group study in women suffering from climacteric symptoms. The subjects were treated with Trisequens for 4 mth prior to randomized assignment to 1 of 2 treatment groups, and with either Trisequens or Kliogest for 12 mth thereafter. Forty-one (41) patients were initially recruited for the study. Of these, 34 completed the study, each treatment group hence comprised 17 women. The results suggest that continuous treatment is as effective as sequential treatment in alleviating climacteric symptoms. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were significantly reduced after changeover from sequential to continuous treatment (LH: P less than 0.001; FSH: P less than 0.01). Breast cancer was detected in 2 women, 1 being from each treatment group. Weight, blood pressure and cholesterol concentrations were not significantly altered in either of the groups. There were no cases of endometrial hyperplasia. In the continuous-treatment group a temporary increase in breakthrough bleeding occurred at the beginning of the treatment period. It was concluded that continuous treatment seems to constitute an efficacious regimen for climacteric symptoms, which does not induce monthly bleeding.

Metronidazole in the treatment of non-specific vaginitis (NSV).

In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.

[Comparison between the combined pill and intrauterine device in nulliparae under the age of 19]. / Sammenligning av kombinasjonspille og intrauterin prevensjon hos nulliparae under 19 år.

PIP: A study of oral contraceptive (o.c.) and IUD use among single nulliparae, 14-18 years of age, is presented. 100 women were prescribed a combination preparation, and Copper T IUDs were inserted in 100 women. 33%-40% had not previously used any form of contraception. 9 of the o.c. group and 14 of the IUD group had undergone abortion before. There were no pregnancies in either group throughout the observation period of 955 months for the o.c. group and 1134 months for the IUD group. The most common side effects in the o.c. group were weight gain, depression, nausea, and decreased libido; 44 reported no side effects. Pain increased menstrual bleeding, and fluor were the most commonly reported side effects in the IUD group; 21 reported no side effects. The IUDs were expelled in 17 cases, in 12 of which they were immediately reinserted. 4 cases of salpingitis were reported in the IUD group. 68 in the IUD group said they were satisfied with the contraceptive method, compared to 59 in the o.c. group. The continuation rate was 75% for the IUD group after an average 13.2 months of observation and 55% in the o.c. group after an average 12.7 months of observation.^ieng